跳至主要内容
临床试验/NCT04529122
NCT04529122已完成不适用

A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)

Hoffmann-La Roche281 个研究点 分布在 13 个国家目标入组 7,864 人开始时间: 2020年8月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
7,864
试验地点
281
主要终点
Overall Survival

研究概览

简要总结

WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant is an adult (according to the age of majority as defined by local regulations)
  • Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
  • Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
  • Informed consent has been obtained from the participant or legally authorized representative, as per local regulations

排除标准

  • Participant has a prior or current diagnosis of haematological malignancy

结局指标

主要结局

Overall Survival

时间窗: From date of registry entry until death, for up to 5 years

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (281)

Loading locations...

相似试验

A Worldwide Cancer Registry Enrolling Participants... | 临床试验